Blueprint Medicines has taken an unusual route to raising cash for its R&D pipeline – selling off some of the royalties from its already-approved medicines in return for a cash injectio
Biopharma initial public offerings are back with a bang after a coronavirus pandemic lull, as Royalty Pharma raised a record-breaking $2.2 billion from the sale of 77 million s
The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS